Navigation Links
Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Date:12/9/2009

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

"The efficacy and safety data from the Tulip PETAL Study are consistent with what we have seen in our previous elagolix studies. Women recognize significant improvement in endometriosis symptoms across multiple time points using elagolix, coupled with an excellent safety profile," said Chris O'Brien, M.D., Chief Medical Officer at Neurocrine. "Although certain daily efficacy scales employed in this trial will not be used in subsequent trials, we have and will continue to obtain important information from this Phase 2 study. Given the placebo response in some of the secondary efficacy endpoints, we plan to perform extensive analyses to understand the differences between North American and Central Eastern European clinical trial sites and subjects, the impact of trial design differences and patient baseline characteristics, and continue our assessment of appropriate statistical methods as we plan for our pivotal trials."

Tulip PETAL Study Design and Baseline Characteristics

The Tulip PETAL study was conducted in six countries in the Eastern European region (Romania, Poland, Ukraine, Hungary, Russia and Bulgaria). The study randomized 174 patients with a laparoscopic diagnosis of endometriosis into four treatment arms: elagolix 150 mg once daily, elagolix 250 mg once daily, leuprorelin monthly depot (Prostap SR®), or placebo; in a double-blind, double-dummy design. After completion of the initial three months of treatment, place
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Neurocrine Biosciences Amends Corporate Headquarters Lease
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Secures Committed Equity Financing Facility
4. Neurocrine Biosciences Reports Second Quarter 2009 Results
5. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
7. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
8. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
9. Neurocrine Biosciences Reports First Quarter 2009 Results
10. Neurocrine Announces Work Force Restructuring
11. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 29, 2014 Global polyvinyl chloride ... world economic crisis during 2008-2009, especially in North America ... and currently is keeping to a growing trend. , ... is utilized in the construction segment. In 2013, the ... profiles, tubing, sheets and rigid film. Moreover, the PVC ...
(Date:10/30/2014)... 30, 2014 James Sherley says he has ... tissue stem cell technology since his days as a principal ... in the late 1990’s. Sherley founded the ASCTC as ... holds all the intellectual property developed in Sherley’s research over ... Massachusetts Institute of Technology (MIT), and more recently as a ...
(Date:10/30/2014)... CARLSBAD, Calif. , Oct. 30, 2014 Isis ... antisense therapeutics, today announced that management will present a company ... 2014 at 8:30 a.m. ET in Boston, MA. ... will be available on the "Investors & Media" section of ... available on the Isis website within 48 hours and will ...
(Date:10/27/2014)... Ryan Carfley , Managing Partner at ... down with Bryan Hamilton, the publisher of the Triangle Business ... in the Research Triangle region of North Carolina. , Just ... the roundtable include the role of social media in ... balance and the unique role that Millennials play in the ...
Breaking Biology Technology:Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3
... 2011 Bayer HealthCare,s affiliate MEDRAD, Inc. today ... demonstrated a 59 percent relative reduction in target ... patients with peripheral arterial disease (PAD) treated with ... compared to standard balloon angioplasty (POBA). Additionally, for ...
... SAN DIEGO, Nov. 10, 2011 Verenium Corporation (Nasdaq: ... focused on the development and commercialization of high-performance enzymes, ... financial results for the third quarter and nine months ... strong financial and operational progress in the first nine ...
... GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical ... Human Immunodeficiency Virus (HIV) infections, today announced its financial ... GeoVax reported a net loss of $375,852 ... 30, 2011, compared to $644,666 ($0.04 per share) for ...
Cached Biology Technology:Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon 2Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon 3Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon 4Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 2Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 3Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 4Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 5Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 6Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 7Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 8Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 9GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 2GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 3GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 5
(Date:10/29/2014)... as a consequence of chemotherapy will benefit from a ... technology that prevents hair loss. , The research is ... scalp cooling manufacturing company, Paxman Coolers, of Fenay Bridge, ... University of Huddersfield. , The research will be led ... in the pharmacology of cancer treatment, which he will ...
(Date:10/29/2014)... Beaverton, OR) New research presented at the ... in Houston, TX showed for the first time ... in women using a readily available nutritional supplement, ... by Dr. Judith A. Smith, Pharm.D., associate professor ... Sciences at The University of Texas Health Science ...
(Date:10/29/2014)... and environmental, have been blamed for increasing the ... as a family history of schizophrenia, are widely ... gondii , a parasite transmitted by soil, undercooked ... skepticism. , A new study by Gary Smith, ... University of Pennsylvania,s School of Veterinary Medicine, used ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... that died 44,000 years ago in Antarctica have provided ... traditional genetic aging measurements, and suggest those approaches have ... 200 to 600 percent. In other words, a ... 100,000 years old may actually be 200,000 to 600,000 ...
... -- Agricultural soils accumulate trace metals, particularly copper ... wastes (sewage biosolids and manures) and fungicides that are ... for tolerable concentrations of these potentially plant-toxic elements in ... effects of the metals are substantially independent and not ...
... and LAS VEGAS, Nov. 9 CBS Vision, the ... Media Group company, today announced a new research partnership that will ... housed in the MGM Grand Hotel in Las Vegas. , ... one of the county,s leading agencies, will be called Communications ...
Cached Biology News:Ancient penguin DNA raises doubts about accuracy of genetic dating techniques 2Additive copper-zinc interaction affects toxic response in soybean 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 3CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 4
... [RS17 ] to PRKAR2 cAMP is ... of cellular functions. cAMP exerts its effects ... which transduces the signal through phosphorylation of ... AMPK is a tetramer composed of two ...
... Rocking Shaker provides the exact agitation ... The very slow to fast speed ... provide a gentle wave motion that ... blotted membranes to achieve faster, more ...
...
... Have you bought a Perkin Elmer UltraVIEW ... using the Andor iXon and iQ software? No ... that upgrade. You keep your existing microscope, lasers, ... will customise it to work with our precision ...
Biology Products: